Abstract: . . .  10:45 -11:10 a.m. Coffee Break Therapeutic Targets and Approaches 11:10 -11:40 a.m. ACE Inhibition and Angiotensin Receptor Blockade ................ Marc A. Pfeffer, M.D., Ph.D. 11:40 -11:50 a.m. Discussion 11:50 -12:20 p.m. Genetic Determinants of Arterial Thrombosis .............................................. Joseph Loscalzo, M.D., Ph.D. 12:20 -12:30 p.m. Discussion 12:30 - 1:00 p.m. Cholesterol Lowering in Atherosclerosis: Is Lower Really Better? ................. Eugene Braunwald, M.D. 1:00 - 1:10 p.m. Discussion Clinical Approach to Disease Management 1:10 - 2:10 p.m. Lunch 2:10 - 2:30 p.m. Percutaneous Coronary Interventions ..................................................... Laura Mauri, M.D., MSC 2:30 - 2:40 p.m. Discussion 2:40 - 3:00 p.m. Antiplatelet Monitoring ................... Daniel I. Simon, M.D. 3:00 - 3:10 p.m. Discussion 3:10 - 3:30 p.m. . . .
. . .  .......................................................... Mary Cushman, M.D. 11:55 -12:05 p.m. Discussion 12:05 -12:35 p.m. Diagnosis of Pulmonary Embolism .................................................... Henri Bounameaux, M.D. 12:35 -12:40 p.m. Discussion 12:40 - 1:10 p.m. Risk Stratification of Pulmonary Embolism .............................. Samuel Z. Goldhaber, M.D. 1:10 - 1:20 p.m. Discussion 1:20 - 2:20 p.m. Lunch 2:20 - 2:50 p.m. Prevention of Venous Thromboembolism Embolism .............................. Samuel Z. Goldhaber, M.D. 2:50 - 3:00 p.m. Discussion Miniupdates 3:00 - 3:15 p.m. Direct Thrombin Inhibitors: Bivalirudin, Lepirudin, Argatroban ...................... David J. Kuter, M.D. 3:15 - 3:20 p.m. Discussion 3:20 - 3:35 p.m. Injectable anti-Xa Agents: Fondaparinux, Idraparinux ...................................... James Bradner, M.D. 3:35 - 3:40 p.m. Discussion . . .
. . .  Lake City, Utah Stavros V. Konstantinides, Associate Professor of Medicine, Vice-Chairman, Department of Cardiology and Pulmonary Medicine, George August University of Goettingen, Goettingen, Germany Daniel I. Simon, Herman K. Hellerstein Professor of Medicine; Director, Case Cardiovascular Center, Case School of Medicine; Chief, Division of Cardiology, University Hospitals of Cleveland/Case School of Medicine Jeffrey Weitz, Director of the Experimental Thrombosis and Atherosclerosis (ETA) Programme, Director, Henderson Research Center, Hamilton, Ontario, Canada  . . .
--3000,3,500,2863,16030